private:theravectys
|
969169
|
Dec 3rd, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Dec 3rd, 2020 02:58PM
|
Dec 3rd, 2020 02:58PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Dec 2nd, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Dec 2nd, 2020 04:46PM
|
Dec 2nd, 2020 04:46PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Dec 1st, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Dec 1st, 2020 03:17PM
|
Dec 1st, 2020 03:17PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Nov 30th, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Nov 29th, 2020 09:17PM
|
Nov 30th, 2020 04:05PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Nov 28th, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Nov 28th, 2020 04:51PM
|
Nov 28th, 2020 04:51PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Nov 27th, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Nov 27th, 2020 01:17PM
|
Nov 27th, 2020 01:17PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Nov 26th, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Nov 25th, 2020 08:16PM
|
Nov 25th, 2020 08:16PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Nov 24th, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Nov 24th, 2020 03:49PM
|
Nov 24th, 2020 03:49PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Nov 23rd, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Nov 23rd, 2020 05:38PM
|
Nov 23rd, 2020 05:38PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|
private:theravectys
|
969169
|
Nov 22nd, 2020 12:00AM
|
THERAVECTYS
|
2.2K
|
19.00
|
Open
|
Biotechnology
|
Nov 22nd, 2020 04:34PM
|
Nov 22nd, 2020 04:34PM
|
THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology.
Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the Pasteur Institute, TheraVectys leverages its unique proprietary platform to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Taking full advantage of its technology’ and IP’s versatility, TheraVectys implements a broad portfolio, building on strategic partnering to lead PoC-validated vaccine-candidates to clinical trials and to market.
With an extensive range of developments in infectious diseases and oncology indications, TheraVectys is positioned to profoundly and sustainably transform global health.
|
Open
|
Biotechnology, Oncology, Therapeutic vaccines, Infectious Diseases, Prophylactic vaccines , Immunotherapy, Tropical Diseases, Lentiviral vectors
|
Open
|
3 rue de l'arrivée, , BP 033
|
Paris Cedex 15
|
Ile-de-France
|
FR
|
75749
|
|
THERAVECTYS
|
|
Pharmaceuticals & Biotechnology
|